🔬 Uncovering the Hidden Risk: The Stanford Study Explained

A groundbreaking study from Stanford Medicine has revealed a startling connection between color vision deficiency, commonly known as colorblindness, and increased mortality from bladder cancer. Published in Nature Health on January 15, 2026, the research analyzed vast electronic health records to uncover why individuals with colorblindness face a 52% higher risk of death over 20 years after a bladder cancer diagnosis compared to those with normal color vision.Stanford Medicine News

Lead author Mustafa Fattah, a medical student at Columbia University Vagelos College of Physicians and Surgeons, along with senior author Ehsan Rahimy, MD, an adjunct clinical associate professor of ophthalmology at Stanford, and collaborators from Beaumont Health and Stanford's Byers Eye Institute, used the TriNetX platform. This database aggregates de-identified records from over 275 million patients worldwide, starting with about 100 million from the United States.

Researchers identified 135 patients diagnosed with both color vision deficiency and bladder cancer, matching them one-to-one with patients who had bladder cancer but normal vision. Controls were balanced for age, sex, race, ethnicity, and comorbidities like hypertension, diabetes, and smoking history using propensity score matching. Kaplan-Meier survival analysis showed significantly lower survival probabilities for the colorblind group (χ² = 4.85, P = 0.028), with a 20-year mortality risk ratio of 1.52 (95% CI: 1.05–2.19, P = 0.025).

Crucially, the same analysis for colorectal cancer—where blood in stool can also be a sign—showed no significant difference, highlighting that the issue is specific to bladder cancer's primary symptom: painless blood in the urine, or hematuria, noticed by 80-90% of patients initially.

This discovery underscores how a seemingly benign vision condition can mask a life-threatening warning, delaying diagnosis and treatment.

Understanding Color Vision Deficiency

Color vision deficiency (CVD), or colorblindness, is not full blindness to color but a reduced ability to distinguish certain hues, most commonly red and green. It affects approximately 1 in 12 men (about 8%) and 1 in 200 women (0.5%), stemming from genetic variations on the X chromosome, making it far more prevalent in males. Those affected often struggle with shades of red, appearing brownish or grayish, which can blend seamlessly with urine's natural yellow tones.

Many people with CVD function well daily, compensating intuitively, and may never receive a formal diagnosis since routine eye exams don't always test for it. Ishihara plates—dot patterns with hidden numbers visible only to those with normal vision—are the standard test. However, as senior author Ehsan Rahimy notes, "Most people with color vision deficiency are typically functioning fine. They don't have any other vision issues. Many affected individuals may not even know they have it."

Prior small studies supported this link: a 2001 experiment found colorblind participants detected simulated blood in samples only 70% of the time versus 99% for normal vision, and a 2009 review of 200 male bladder cancer patients noted later-stage diagnoses among the colorblind.

• Types: Protanomaly (red-weak), protanopia (no red), deuteranomaly (green-weak), deuteranopia (no green).
• Causes: Usually inherited (X-linked recessive), but can be acquired from diseases like diabetes or medications.
• Daily impacts: Traffic lights, clothing choices, but rarely health self-monitoring.

For bladder cancer detection, this red perception gap is critical, as fresh blood turns urine pink, red, or cola-colored—shades hard to spot for many with CVD.

Bladder Cancer Basics: A Silent Threat

Bladder cancer is the 10th leading cause of cancer deaths in the US, with an estimated 85,000 new diagnoses in 2025 alone. It affects men four times more than women, often striking those over 55, smokers, or exposed to chemicals like dyes or arsenic. The bladder, a muscular sac holding urine, develops tumors usually from urothelial cells lining it.

Early stages are highly treatable—over 75% five-year survival if caught non-invasive—but advanced invasion drops to under 15%. The hallmark symptom is gross hematuria: visible blood in urine without pain, prompting 80-90% of diagnoses. Microscopic hematuria (invisible to eye) is caught via tests, but self-detection of gross changes drives early care.

Risk factors include:

• Tobacco use (50% of cases).
• Occupational exposures (e.g., painters, machinists).
• Chronic bladder irritation (infections, stones).
• Family history or genetic syndromes.

Diagnosis involves cystoscopy (scope into bladder), biopsy, and imaging. Treatment ranges from transurethral resection for early tumors to chemotherapy, immunotherapy, or cystectomy for advanced.

Without early hematuria notice, tumors progress silently, explaining worse outcomes for colorblind patients.

Photo by Abdulai Sayni on Unsplash

Why Colorblindness Delays Bladder Cancer Detection

The study's hypothesis—that missing red blood in urine leads to delayed medical seeking—is compelling. Colorblind individuals may dismiss subtle color shifts as normal variation, unlike those with full vision who act promptly. Rahimy explains: "The power in this type of study is the ability to curate a particular population of interest... when you're casting a net in an ocean’s worth of data, you have a better shot at capturing a rare fish."

Limitations temper findings: Small sample (135 pairs), reliance on ICD-10 codes (H53.5 for CVD, C67 for bladder cancer), potential under-diagnosis of CVD, no staging data, and all-cause mortality. Yet, the 52% higher risk holds after matching, suggesting real impact.

Contrast with colorectal cancer: Multiple symptoms (abdominal pain in 66%, bowel changes in 50%+) and screening (colonoscopy from age 45) mitigate reliance on blood-in-stool visibility.

🎯 Actionable Advice for At-Risk Individuals

If you have color vision deficiency, proactive steps can bridge the detection gap:

• Request annual urinalysis at checkups to catch microscopic blood.
• Ask healthcare providers to include CVD history in cancer screenings—urologists and primary care should inquire.
• Enlist a trusted partner or family member to visually inspect urine periodically, especially if over 50 or high-risk.
• Monitor for other signs: frequent urination, urgency, pelvic pain.
• Use home dipstick tests for blood, though not foolproof for colorblind users—opt for lab confirmation.

Rahimy advises: "If you don’t trust yourself to know that there’s a change in the color of your urine, it could be worth having a partner or somebody you live with periodically checking it for blood." For undiagnosed suspects, take an online Ishihara test and consult an ophthalmologist.

Healthcare pros: Add CVD questions to intake forms, as Rahimy hopes: "I’m hopeful that this study raises some awareness, not only for patients with colorblindness, but for our colleagues who see these patients."

Broader Healthcare and Research Implications

This study spotlights how sensory impairments affect health equity. Routine screenings overlook vision variances, but simple adaptations—like standardized urine checks—could save lives. Funded by NIH (P30-EY026877) and Research to Prevent Blindness, it calls for prospective trials on CVD-specific bladder cancer screening.

In academia, such interdisciplinary work (ophthalmology-urology) thrives. Aspiring researchers can explore opportunities in research jobs or clinical research jobs at institutions like Stanford. Medical students like Fattah exemplify paths via higher ed faculty positions or professor jobs.

Public awareness campaigns could amplify impact, much like colorectal screening success. As Rahimy says, "If this study raises awareness and people read this and casually pass it along, I think it’s done its job."

Photo by Abdulai Sayni on Unsplash

Key Takeaways and Next Steps

The Stanford study proves colorblindness can hide bladder cancer's red flag, hiking mortality by 52%. Awareness, routine tests, and partner checks offer solutions. Stay vigilant—early detection transforms outcomes.

For career inspiration in health research, check Rate My Professor for insights on leading experts, browse higher ed jobs, or explore higher ed career advice. Share your thoughts in the comments below and visit university jobs or post a job to connect with the academic community driving discoveries like this.

Related reads: Young Adult Cancer Survival, HPV Vaccine Cancer Prevention.